The present study enriched the research data on PD-1 inhibitors in the first-line treatment of ES-SCLC after the inclusion of the results of tislelizumab and toripalimab, but PD-1 + Chemo versus PD-L1 + Chemo did not produce a significant improvement in OS and PFS. Here, PDCD1 is linked to small cell lung carcinoma.